Terms of use

Shire is pleased to provide you with this web site and its content for general informational purposes. Please carefully read these Terms and Conditions relating to the use of our web site. Shire will use reasonable efforts to ensure that the information is accurate at the time it is added to the web site. Please note, however, that Shire makes no warranties or representations that the information is accurate and accepts no liability for any errors or omissions in the content of the site or any losses or damage that may arise from relying on this information. The information may be changed by Shire at any time. By using this web site, you agree to these Terms and Conditions without limitation or qualification.

Use of Materials and Intellectual Property Rights

The copyright in this web site belongs to Shire. All other intellectual property rights are reserved. Shire authorizes you to copy materials published on this web site for noncommercial use only, provided that any copy of these materials which you make retains all copyright and other proprietary notices.

Links to Third Party Web Sites

The web site may from time to time contain hypertext-links to third parties’ web sites. Shire is not responsible for, and accepts no liability in respect of, any information or opinion contained on any other such web site. As Shire has no control over such web sites and because their content is subject to change without notice to Shire, it is the responsibility of the user of the web site to ensure that any information accessed is accurate and that software which is downloaded from that web site is free of viruses or any other items of a destructive nature. Shire accepts no liability whatsoever in respect of any loss, damage, costs or liability incurred through any such downloaded material.

Information Is No Substitute for Consulting a Health Professional

The information on the web site is intended only to provide knowledge of disease information. This information should not be considered complete and should not be used in place of a visit, call, consultation, or advice of your physician or other health care provider. Shire does not recommend the self-management of health problems. Should you have any health care-related questions, please call or see your physician or other health care provider promptly. You should never disregard medical advice or delay in seeking it because of something you have read here. Information is not necessarily accurate, complete, or current.

Information accessed on the web site is not exhaustive. Shire makes reasonable efforts to include accurate and current information, wherever possible, but makes no warranties or representations as to its accuracy or completeness. This information is provided “as is” without warranty of any kind, either express or implied, including but not limited to implied warranty of fitness for a particular purpose. Shire is not responsible for computer damage resulting from using the web site.

Shire makes no representation or warranty that access to the web site will be available on a timely basis, will be uninterrupted, or will be error-free. Shire does not warrant that these pages, or the server that makes them available, are free of viruses or other harmful elements. In no event shall Shire, its affiliates and subsidiaries, and their respective officers directors, employees, agents, representatives, information providers, and licensors and their respective heirs and assigns, be liable for any direct, indirect, incidental, consequential, exemplary, special, punitive, or other damages even if informed of the possibility of such damages. The above exclusion may not apply in jurisdictions to the extent that they do not allow the exclusion of implied warranties.

Any personally identifiable information in electronic communications to this web site is governed by Shire’s Privacy Notice. Shire shall be free to use or copy all other information in any such communications, including any ideas, inventions, concepts, techniques or know-how disclosed therein, for any purposes, including disclosure to third parties and/or developing, manufacturing and/or marketing products or services. Information intended for US residents only.

All materials and information appearing on the web site are intended for US residents only. These Terms and Conditions were last updated: February 4, 2009.

Shire is not responsible for the terms and conditions, privacy policy, or content of any website not owned by Shire. Shire has no control over and does not endorse the results or contents of any hashtag search or use of hashtags on social media.

Indication:
GATTEX® (teduglutide) for injection is indicated for the treatment of adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.

Important Safety Information:

Warnings and Precautions:
GATTEX has been associated with possible acceleration of neoplastic growth, intestinal obstruction, biliary and pancreatic disease, fluid imbalance and fluid overload, and increased absorption of concomitant oral medication. Click here for additional Important Safety Information.

Click here for additional Important Safety Information.

Indication

GATTEX® (teduglutide) for injection is indicated for the treatment of adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.

Important Safety Information

Warnings and Precautions

Acceleration of neoplastic growth

Colorectal polyps were identified during clinical trials. There is a risk for acceleration of neoplastic growth. Within 6 months prior to starting treatment with GATTEX, colonoscopy (or alternate imaging) of the entire colon with removal of polyps should be performed and follow-up colonoscopy (or alternate imaging) is recommended at the end of 1 year of GATTEX. Subsequent colonoscopies should be performed every 5 years or more often as needed. In case of intestinal malignancy (GI tract, hepatobiliary, pancreatic), discontinue GATTEX. The clinical decision to continue GATTEX in patients with non-gastrointestinal malignancy should be made based on benefit-risk considerations.

Intestinal obstruction

Intestinal obstruction has been reported in clinical trials and postmarketing. In patients who develop intestinal or stomal obstruction, GATTEX should be temporarily discontinued pending further clinical evaluation and management.

Biliary and pancreatic disease

Cholecystitis, cholangitis, cholelithiasis, and pancreatitis have been reported in clinical trials and postmarketing. Laboratory assessment (bilirubin, alkaline phosphatase, lipase, amylase) should be obtained within 6 months prior to starting GATTEX. Subsequent laboratory tests should be done every 6 months or more often as needed. If clinically meaningful changes are seen, further evaluation is recommended including imaging, and continued treatment with GATTEX should be reassessed.

Fluid imbalance and fluid overload

Fluid overload and congestive heart failure have been observed in clinical trials. If fluid overload occurs, especially in patients with underlying cardiovascular disease, parenteral support should be adjusted and GATTEX treatment reassessed. If significant cardiac deterioration develops while on GATTEX, continued GATTEX treatment should be reassessed.

Discontinuation of treatment with GATTEX may also result in fluid and electrolyte imbalance. Fluid and electrolyte status should be monitored in patients who discontinue treatment with GATTEX.

Increased absorption of concomitant oral medication

In clinical trials, one patient receiving prazepam concomitantly with GATTEX experienced dramatic deterioration in mental status progressing to coma during first week of GATTEX therapy. Patients receiving concomitant oral drugs requiring titration or with a narrow therapeutic index should be monitored for adverse reactions due to potential increased absorption of the concomitant drug. The concomitant drug may require a reduction in dosage.

Adverse Reactions

The most common adverse reactions (≥10%) with GATTEX are abdominal pain, nausea, upper respiratory tract infection, abdominal distension, injection site reaction, vomiting, fluid overload, and hypersensitivity.

Use in Specific Populations

Breastfeeding is not recommended during treatment with GATTEX.

Please click here for full Prescribing Information.